MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

Search

Ipsen SA.

Avatud

SektorRahandus

105.6 -2.22

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

105

Max

108.4

Põhinäitajad

By Trading Economics

Sissetulek

-118M

114M

Müük

71M

1.8B

P/E

Sektori keskmine

24.918

22.015

Dividenditootlus

1.12

Kasumimarginaal

6.249

Töötajad

5,358

EBITDA

228M

710M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+16.14% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.12%

3.90%

Turustatistika

By TradingEconomics

Turukapital

8.8B

Eelmine avamishind

107.82

Eelmine sulgemishind

105.6

Uudiste sentiment

By Acuity

33%

67%

104 / 542 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Ipsen SA. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ipsen SA. Prognoos

Hinnasiht

By TipRanks

16.14% tõus

12 kuu keskmine prognoos

Keskmine 123.57 EUR  16.14%

Kõrge 145 EUR

Madal 110 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi Ipsen SA. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

7 ratings

2

Osta

4

Hoia

1

Müü

Tehniline skoor

By Trading Central

105.5 / 108.6Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

104 / 542 Pingereas Rahandus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.